4.20

11.41% 0.43

Pre-market: 4.18 -0.02 -0.48%

Trisalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

Trisalus Life Sciences Inc stock is traded at $4.20, with a volume of 655.08K. It is up +11.41% in the last 24 hours and up +56.72% over the past month. TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Previous Close:

$3.77

Open:

$3.87

24h Volume:

655.08K

Relative Volume:

1.77

Market Cap:

$257.95M

Revenue:

$45.15M

Net Income/Loss:

$-39.23M

P/E Ratio:

-2.2963

EPS:

-1.829

Net Cash Flow:

$-18.93M

1W Performance:

+30.84%

1M Performance:

+56.72%

6M Performance:

-42.54%

1Y Performance:

-19.08%

1-Day Range:

$3.77

$4.455

1-Week Range:

$3.15

$4.455

52-Week Range:

$2.20

$7.95

Trisalus Life Sciences Inc Stock (TLSI) Company Profile

Name

Trisalus Life Sciences Inc

Sector

Healthcare (1104)

Industry

Medical Devices (141)

Phone

415 336 8917

Address

6272 WEST 91ST AVENUE, WESTMINSTER

Employee

102

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

TLSI's Discussions on Twitter

Compare TLSI vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLSI Trisalus Life Sciences Inc	4.20	257.95M	45.15M	-39.23M	-18.93M	-1.829
ABT Abbott Laboratories	88.67	154.45B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	307.94	118.05B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	80.38	103.20B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	46.76	69.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.28	49.68B	6.30B	1.07B	1.09B	1.8406

Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Nov-11-24	Initiated	ROTH MKM	Buy
Oct-25-24	Initiated	Northland Capital	Outperform
Sep-16-24	Initiated	Oppenheimer	Outperform
May-30-24	Initiated	Canaccord Genuity	Buy

View All

Trisalus Life Sciences Inc Stock (TLSI) Latest News

Jun 14, 2026

TriSalus Life Sciences Warrants (TLSIW) Hold Steady Near Support in Quiet TradingAndrews Pitchfork - newsline.com

Jun 14, 2026

Jun 13, 2026

TLSI Q1 2026 Earnings: EPS Surprise of 118.86% Drives Stock HigherAnalyst Drop Coverage - newsline.com

Jun 13, 2026

TriSalus Life Sciences (TLSI) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by 118.86% - newsline.com

Jun 13, 2026

Jun 12, 2026

TriSalus Life Sciences (TLSI) Gains 2.88% as Stock Approaches Key Resistance LevelWave Extension - newsline.com

Jun 12, 2026

Jun 11, 2026

TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus

Jun 11, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire

Jun 11, 2026

Jun 10, 2026

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer - Stock Titan

Jun 10, 2026